Results 181 to 190 of about 9,514 (200)

Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents

EBioMedicine, 2018
Mrinal Patnaik, Raajit Rampal, Pierre Fenaux   +2 more
exaly  

Clinical Results of Hypomethylating Agents in AML Treatment

Journal of Clinical Medicine, 2015
Marjan Cruijsen, Michael Lubbert, Gerwin Hüls   +2 more
exaly  

Hypomethylating Agents

2008
openaire   +1 more source

Epigenetics in focus: Pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents

Critical Reviews in Oncology/Hematology, 2013
Clara Nervi, Valeria Santini, Jaroslaw Maciejewski   +2 more
exaly  

LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents

Leukemia and Lymphoma, 2020
Kelly Chien, Kelly Soltysiak, Rashmi Kanagal-Shamanna   +2 more
exaly  

Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings

Expert Opinion on Pharmacotherapy, 2017
Steven Gore, Thomas Prebet, Abhay Singh   +2 more
exaly  

Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole?

Expert Review of Hematology, 2020
Amer M Zeidan, Jan Philipp Bewersdorf
exaly  

Management of myelodysplastic syndromes after failure of response to hypomethylating agents

Therapeutic Advances in Hematology, 2019
Guillermo Montalban-Bravo
exaly  

Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents—a multicenter historical prospective study

Annals of Hematology, 2019
Odelia Amit, Irit Avivi, Ron Ram
exaly  

The highs and lows of venetoclax with hypomethylating agents for refractory AML

Leukemia Research, 2020
openaire   +2 more sources